Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H19N5O2 |
| Molecular Weight | 385.4186 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1N2N=CC(C(=O)C3=CC=CC(=C3)C#N)=C2N)C(=O)NC4CC4
InChI
InChIKey=VGUSQKZDZHAAEE-UHFFFAOYSA-N
InChI=1S/C22H19N5O2/c1-13-5-6-16(22(29)26-17-7-8-17)10-19(13)27-21(24)18(12-25-27)20(28)15-4-2-3-14(9-15)11-23/h2-6,9-10,12,17H,7-8,24H2,1H3,(H,26,29)
Acumapimod (BCT-197) is an oral p38 MAP kinase inhibitor and an anti-inflammatory agent developed by Mereo BioPharma that has completed Phase 2 development as first-line therapy for severe acute exacerbations of chronic obstructive pulmonary disease. Another study on acute kidney injury in patients undergoing cardiac surgery had been discontinued. Acumapimod is an inhibitor of p38a with an IC50 value < 1 uM. Previous studies undertaken by Novartis, showed the drug has the capacity to reduce the inflammatory marker TNFα and to increase FEV1.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: LPS‐induced TNFα secretion Sources: https://www.ncbi.nlm.nih.gov/pubmed/26904383 |
115.0 nM [IC50] | ||
Target ID: CHEMBL260 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26904383 |
12.0 nM [IC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25599809
The effects of single doses of 20 and 75 mg acumapimod ± prednisone, were investigated in COPD patients
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25599809
Acumapimod is an inhibitor of p38a with an IC50 value < 1 uM.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11338127
Created by
admin on Mon Mar 31 22:05:54 GMT 2025 , Edited by admin on Mon Mar 31 22:05:54 GMT 2025
|
PRIMARY | |||
|
DB15448
Created by
admin on Mon Mar 31 22:05:54 GMT 2025 , Edited by admin on Mon Mar 31 22:05:54 GMT 2025
|
PRIMARY | |||
|
300000025633
Created by
admin on Mon Mar 31 22:05:54 GMT 2025 , Edited by admin on Mon Mar 31 22:05:54 GMT 2025
|
PRIMARY | |||
|
C166567
Created by
admin on Mon Mar 31 22:05:54 GMT 2025 , Edited by admin on Mon Mar 31 22:05:54 GMT 2025
|
PRIMARY | |||
|
836683-15-9
Created by
admin on Mon Mar 31 22:05:54 GMT 2025 , Edited by admin on Mon Mar 31 22:05:54 GMT 2025
|
PRIMARY | |||
|
CHEMBL3545226
Created by
admin on Mon Mar 31 22:05:54 GMT 2025 , Edited by admin on Mon Mar 31 22:05:54 GMT 2025
|
PRIMARY | |||
|
2F16KW647L
Created by
admin on Mon Mar 31 22:05:54 GMT 2025 , Edited by admin on Mon Mar 31 22:05:54 GMT 2025
|
PRIMARY | |||
|
9917
Created by
admin on Mon Mar 31 22:05:54 GMT 2025 , Edited by admin on Mon Mar 31 22:05:54 GMT 2025
|
PRIMARY |
ACTIVE MOIETY